SAN FRANCISCO - Shareholders in a securities class action have failed to plead any of their federal securities law claims in connection with a biotechnology company's alleged issuance of misrepresentations regarding the development of a DNA sequencing system, a federal judge in California ruled April 15 (Thomas J. Primo, et al. v. Pacific Bionsciences of California Inc., et al., No. 11-6599, N.D. Calif.; 2013 U.S. Dist. LEXIS 53643)....(read more)![]()
↧